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Dissemination of definitions and concepts
of allergic and hypersensitivity conditions
Luciana Kase Tanno1,2,3*, Moises A. Calderon4, Helen E. Smith5, Mario Sanchez-Borges6, Aziz Sheikh7,
Pascal Demoly2,3 and on behalf of Joint Allergy Academies
Abstract
Background: Allergy and hypersensitivity can affect people of any age and manifest with problems in a range
of organ systems. Moreover, they can have a significant impact on the quality of life of patients and their families.
Although once rare, there is presently an epidemic of allergic disorders with associated considerable societal
consequences.
Our understanding of the pathophysiology of these disorders has changed substantially over the last 20 years.
In the light of these developments, the Joint Allergy Academies have made concerted efforts to ensure that
these are reflected in the current definitions and concepts used in clinical allergy and to ensure these are reflected
in the forthcoming International Classification of Diseases-11 (ICD-11).
Objective: In this review, we seek to provide an update on the current definitions and concepts in relation to allergic
disorders.
Results: Once the new section has been built in the ICD-11 to address allergic and hypersensitivity conditions, we
have been moving actions to try to support awareness by disseminating updated concepts in the field. Aligned with
the ICD and the WAO philosophy of being global, this document presents fundamental and broad allergy concepts to
strengthen the understanding by different health professionals worldwide, besides to support the formation of in
training students.
Conclusion: This current review intends to be accepted and used universally by all health professionals involved in
diseases’ classification and coding and, therefore, contribute to improve care and outcomes in this increasing
sub-section of the world’s population.
Keywords: Allergy, Hypersensitivity, Allergic conditions, Hypersensitivity conditions, Sensitization
Background
Allergy and hypersensitivity: stating the problems
The importance of disease classification
Many patients have chronic conditions or episodes of ill-
ness in which allergy triggers may be implicated. These
conditions and episodes can be assigned different classi-
fications and terminologies by different healthcare pro-
fessionals. Some of these labels are misrepresentative
labels leading to misconceptions. These varied working
definitions have hampered our real understanding of
these conditions. Inaccurate disease classification can
lead to suboptimal patient care and moreover this mis-
classification can influence the understanding and de-
velopment of allergy (Fig. 1).
In the diagnosis and management of patients, diagnostic
labels are important since they drive investigation and
treatment strategies. The misunderstanding of diseases’
concepts is likely to hamper the indication of diagnostic
method procedures as well as can induce inappropriate
management. For example, using the term wheezy bron-
chitis to describe asthma steers people towards prescrib-
ing antibiotics for exacerbations. Some physicians and
health care professionals consider wheezy bronchitis to be
attributable to bacteria without appreciation that often
viruses such are responsible for symptoms.
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In epidemiology, terminologies and concepts are cur-
rently translated into codes and these data provide mor-
bidity and mortality statistics. These data build a global
picture and are used as the basis of health policy. If the
records are unable to provide reliable data, decreasing the
visibility of some conditions in detriment to others, there
is a possibility of negative outcomes in health decision-
making and management actions, affecting the supply
and demand of goods and services at both national and
global levels. As an example, research showed an
under-notification of anaphylaxis deaths due to difficult
coding under the ICD-10 using the Brazilian national
mortality database, given that there are no anaphylaxis-
specific ICD-10, which are considered valid for coding
underlying causes-of-death [1].
In an economic context, these data are also able to
provide aggregated indicators to understand how the
whole health economy functions and, therefore, influ-
ence directly the allocation of resources for both man-
agement and research. Indeed, the weak identity of the
allergy specialty in the international health classification
and coding systems contributes to the lack of ascertain-
ment and recognition of their importance for healthcare
planning and resource allocation, and prevents clinical
research from being performed, especially in countries in
which allergy is not an academic discipline. For example,
the lack of realistic anaphylaxis mortality epidemiological
data to support public and private decision-making to
offer appropriate treatment, such as auto-injectable adren-
aline, still missing in some countries [1, 2].
In an educational context, although we now have a
culture of evidence-based medicine, the dissemination of
misconceptions of medical terms and definitions, even
informally, can impact negatively in the formation of the
new generations of health professionals. Furthermore, in
today’s world, medical information is widely available
through both print and online media and the source of
information that patients rely on are frequently written
by non-medical professionals or are based on lack of evi-
dence data, what can perpetuate the misconceptions [3].
Evidence for the need of reviewing the allergy and
hypersensitivity definitions and the associated semantic
framework
Allergy and hypersensitivity, previously perceived as sim-
ple and rare disorders, are now common and increas-
ingly a major global public health problem. Numerous
reports over the last 20 years have been indicating that
the world is dealing with an allergy epidemic [4, 5]. They
are complex conditions able to be expressed in many
different organs and in any age, having a significant im-
pact on the quality of life of patients and their families
[6–9]. All health care professionals, in whatever role
may thus encounter patients with allergic conditions.
Concepts in medicine and the new knowledge gener-
ated in the last years [4–50] have substantially changed
our view of the immune system and its interaction with
the environment and external agents (Fig. 2). Such de-
velopments in pathophysiology, pharmacology and clin-
ical practice necessitate reviewing current definitions
and terminologies.
The World Health Organization (WHO) decided for
starting the 11th revision process with the aim of adapt-
ing the ICD frame to the new knowledge generated since
the last revision. However, allergic and hypersensitivity
conditions have not been adequately tracked in the ICD
framework as previously demonstrated [1, 10]. Since 2013,
an international collaboration of Allergy Academies, com-
posed first by the American Academy of Allergy Asthma
and Immunology (AAAAI), the European Academy of
Allergy and Clinical Immunology (EAACI), the World Al-
lergy Organization (WAO), and then by the American
College of Allergy Asthma and Immunology (ACAAI), the
Asia Pacific Association of Allergy, Asthma and Clinical
Fig. 1 Impact of the allergic and hypersensitivity conditions
misconceptions
Fig. 2 Immune system interactions and main clinical outcomes
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Immunology (APAAACI) and the Latin American Society
of Allergy, Asthma and Immunology (SLAAI), has worked
to improve and update the classification of allergies in the
forthcoming ICD-11 version, by providing scientific evi-
dence for the need for changes [1, 10–17]. A major
achievement of this process is the construction of an “Al-
lergic and hypersensitivity conditions” parented subchap-
ter (under the “Disorders of the immune system” chapter)
guided by the World Health Organization (WHO) ICD
representatives [18]. However, during the detailed tech-
nical/scientific labor-intensive building process in which
we had to reach a consensus with all the “sister-special-
ties” with whom we have overlapping conditions, it be-
came clear that definitions and concepts currently used in
routine allergy clinical practice are not broadly known
outside our community.
For all the reasons mentioned above, we have compiled
this review which addresses the concepts and semantic
frameworks of key allergic and hypersensitivity conditions
with the idea that this should be accessible to all health
care professionals in clinical practice, education and re-
search. It is hoped that this revision will be globally ac-
cepted as a tool of improving the communication between
health professionals and also support the tremendous ef-
forts of the Joint Allergy Academies to update and
standardize the allergy and hypersensitivity definitions
throughout the new ICD-11.
The strategy for a better classification of allergic and
hypersensitivity diseases in the ICD-11
The 2004 European Academy of Allergy and Clinical Im-
munology (EAACI) - World Allergy Organization (WAO)
revised nomenclature [19] was the basis of the proposed
document, updated by new knowledge generated since its
publication [19–50]. We also took the advances in the
ICD-11 revision process to support this review manuscript
since all the “allergic and hypersensitivity conditions”
chapter was originally constructed by crowdsourcing the
allergy community leadership [15]. Briefly, after a large
survey of the allergy community [14], the identification of
the gaps and trade-offs in both ICD-10 and ICD-11 beta
phase codes [12] a classification model for allergic and
hypersensitivity conditions has been constructed following
the ICD/WHO rules and validated by crowdsourcing al-
lergist leaderships’ community [17, 51]. The classification
proposal has been presented and endorsed by the WHO
Hypersensitivity
“Conditions clinically resembling allergy that cause objectively 
reproducible symptoms or signs, initiated by exposure to a defined
stimulus at a dose tolerated by normal subjects”
Allergy or allergic hypersensitivity
“Hypersensitivity reaction initiated by 
a proven or strongly suspected
immunologic mechanisms”
Non-allergic hypersensitivity
“Hypersensitivity reaction in which
immune mechanism was excluded” 
IgE-mediated allergy
or IgE- mediated
allergic reaction or
IgE-mediated
allergic 
hypersensitivity
Non-IgE mediated
allergy or non-IgE 
mediated
hypersensitivity
Atopic diseases Non-atopic diseases
Fig. 3 Schematical hierarchy considered for the hypersensitivity, allergy and atopy definitions, adapted from [19]
Table 1 Current definitions for the terms “allergy”, “sensitization”, “atopy” and “atopic diseases”
Conditions Allergy Sensitization Atopy Atopic diseases
Concepts Allergy is a hypersensitivity
reaction initiated by proven
or strongly suspected
immunologic mechanisms.
It can be IgE-mediated or
non-IgE mediated. The triggers
are substances that the subject
has been previously exposed
and sensitized.
Sensitization is considered when
an underlining immune mechanism
is proven by an in vivo or in vitro
procedure methods, such as
presence of specific IgE or T
lymphocyte to an allergen. The
sensitization has to be associated to
a specific compatible clinical history
to lead to the diagnosis of allergy.
Personal and/or familial
tendency, usually in childhood
or adolescence, to become
sensitized and produce IgE
antibodies in response to
ordinary exposures to
allergens, usually proteins.
Development of typical symptoms
of asthma, rhinoconjunctivitis, or
eczema in atopic patients. These
clinical presentations can happen
isolated or in combination and, in
general, have a different course
throughout life.
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Table 2 Current definitions of conditions covered by the allergy specialty and updated to the new ICD-11 “Allergic and hypersensitivity
conditions” chapter
Main groups of allergic
and hypersensitivity
conditions [15, 19]
Definitions for allergic and hypersensitivity conditions
implemented the ICD-11 beta draft platform
Corresponding subchapter into the new “Allergic and
hypersensitivity conditions” ICD-11 chapter (ICD-11
beta draft Foundation September 2015 version) [18]
Rhinitis Rhinitis is an inflammation of the nasal mucosa clinically
characterized by major symptoms: sneezing, nasal pruritus,
running nose, and stuffy nose.
Allergic and hypersensitivity disorders involving the
respiratory tract
Allergic rhinitis Allergic rhinitis is an inflammation of nasal airway triggered by
allergens to which the affected individual has previously been
sensitized. Pathogenesis of allergic rhinitis is type I IgE-mediated
allergy on the nasal mucosa. Antigens inhaled into sensitized
nasal mucosa bind to IgE antibodies on mast cells, which release
chemical mediators such as histamine and leukotrienes. The
main triggers are inhaled allergens, such as house dust mites
and pollens.
Non-allergic rhinitis Non-allergic rhinitis is an inflammation of nasal mucosa in which
allergic mechanisms are not involved. It covers many different
phenotypes and the major symptoms (sneezing, running nose,
and stuffy nose) with variable intensity according to the triggers/
causes.
Asthma Asthma is a clinical syndrome characterized by recurrent attacks
of breathlessness and wheezing or cough, which vary in severity
and frequency from person to person. In an individual, they may
occur from hour to hour and day to day. Allergic and non-
allergic asthma are a heterogeneous group of disorders due to
inflammation of the air passages in the lungs and affects the
sensitivity of the nerve endings in the airways so they become
easily irritated.
Allergic asthma Allergic asthma is the most easily recognized asthma phenotype,
which often commences in childhood and is associated with a
past and/or family history of allergic disease such as eczema,
allergic rhinitis, or food or drug allergy. Examination of the
induced sputum of these patients before treatment often reveals
eosinophilic airway inflammation. The main triggers are inhaled
allergens, such as house dust mites and pollens. Patients with
this asthma phenotype usually respond well to inhaled
corticosteroid (ICS) treatment depending on the severity.
Non-allergic asthma Non-allergic asthma occurs in some patients who have asthma
that is not associated with allergy. The cellular profile of the
sputum of these patients may be neutrophilic, eosinophilic or
contain only a few inflammatory cells (paucigranulocytic).
Patients with non-allergic asthma often respond less well to ICS.
It can cover different phenotypes, such as Aspirin induced
asthma, virus induced asthma, exercise induced bronchospasm.
Conjunctivitis Conjunctivitis is the inflammation of the conjunctiva. It can
have many different causes and can cover both allergic and
non-allergic conjunctivitis. Allergic conjunctivitis is an IgE-
mediated response due to the exposure of seasonal or perennial
allergens in sensitized patients. The allergen-induced inflammatory
response of the conjunctiva results in the release of histamine and
other mediators. Symptoms consist of redness (mainly due to
vasodilation of the peripheral small blood vessels), edema (swelling)
of the conjunctiva, itching, and increased lacrimation
(production of tears). Besides IgE-mediated conjunctivitis,
contact allergic conjunctivitis involving TH1 mechanisms also
occurs.
Allergic or hypersensitivity disorders involving the eye
Dermatitis Local inflammation of the skin, that can cover both immune-
mediated and non-immune mediated conditions.
Allergic or hypersensitivity disorders involving skin and
mucous membranes
Contact dermatitis Allergic contact dermatitis is an eczematous response provoked
by a type IV delayed immune reaction in the skin to a substance
or substances to which the individual has previously been
sensitized.
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revising steering group. The simplified constructed frame-
work was the basis for the construction of the “Allergic
and hypersensitivity conditions” parented subchapter into
the ICD-11 beta draft [18].
Once the new section has been built, we have been
moving actions to try to support awareness by dissemin-
ating updated concepts in the field. Aligned with the
ICD philosophy of being of global use, this document in-
tends to be basic, fundamental and broad to make the
allergy concepts fully understood by different health pro-
fessionals worldwide, besides supports the formation of
in training students.
Although some countries use national modifications
of ICD-10, such as United States of America (ICD-10-
CM), Australia (ICD-10-AM) and Canada (ICD-CA),
they may be advised by the WHO to move to the ICD-
11 once it is available and proven stable. There is a sub-
stantial improvement of allergic and hypersensitivity
conditions codes into the ICD-10 CM when compared
with the ICD-10, even the most recent version of it
[51]. However, we observe that the ICD-10 CM, as well
as most of the other national adaptations, keeps the
same framework, inheriting many trade-offs. The sim-
ple search of the term “Allergy” into both ICD-10 (2016
Table 2 Current definitions of conditions covered by the allergy specialty and updated to the new ICD-11 “Allergic and hypersensitivity
conditions” chapter (Continued)
Non-allergic contact dermatitis is usually due to external irritants;
it is an eczematous reaction provoked by acute or prolonged
and repeated contact with a substance or substances which are
injurious to the skin. Common irritants include defatting agents
(solvents, soaps and detergents), acids (both inorganic and
organic) and alkalis (e.g., sodium hydroxide and wet cement).
Atopic eczema A chronic inflammatory genetically determined eczematous
dermatosis associated with an atopic diathesis (elevated
circulating IgE levels, Type I allergy, asthma and allergic rhinitis).
It is manifested by intense pruritus, exudation, crusting,
excoriation and lichenification. Often presenting in infancy
affecting the face, forearms and lower limbs, it tends to move to
the limb flexures after infancy. Although commonly limited in
extent and duration, it may be generalized and life-long.
Urticaria (or Spontaneous
urticaria)
Urticaria is a disease characterized by the development of
wheals (hives), angioedema, or both. It is classified as acute
when it lasts less than six weeks, and chronic when lasts six
weeks or more. When the reaction is mediated by
immunological mechanisms, the term should be allergic urticaria.
Anaphylaxis Anaphylaxis is a severe, life-threatening systemic hypersensitivity
reaction which is rapid in onset with potentially life-threatening
airway, breathing, or circulatory problems and is usually, although
not always, associated with skin and mucosal changes. It can be
allergic or non-allergic.
Anaphylaxis
Food hypersensitivity Food hypersensitivity reactions are adverse effects of food or
food additives that clinically resemble allergy. Food allergy is
an adverse reaction to food mediated by an immunologic
mechanism, involving specific IgE (IgE-mediated), cell-mediated
mechanisms (non-IgE-mediated) or both IgE- and cell-mediated
mechanisms (mixed IgE- and non-IgE-mediated).
Complex allergic or hypersensitivity conditions
Drug hypersensitivity Drug hypersensitivity reactions are the adverse effects of
pharmaceutical formulations (including active drugs and
excipients) that clinically resemble allergy. It belongs to type B
adverse drug reactions, which are defined by the World Health
Organization as the dose-independent, unpredictable, noxious,
and unintended response to a drug taken at a dose normally
used in humans. It covers many different clinical phenotypes
with variable onset and severity.
Hymenoptera and other
insects hypersensitivity
or allergy
Hymenoptera and other insects’ hypersensitivity cover local
cutaneous reactions (large local reactions) and anaphylaxis due
to contact to the venom (sting, bite) or saliva (bite) of insects
(e.g., bee, wasp, tick). These reactions can be immune mediated
(e.g., IgE-mediated or non-IgE-mediated venom allergy) or
non-immune mediated.
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version) [51] and ICD-10 CM [52] platforms addresses
to the T78 section, entitled “Adverse effects, not else-
where classified”.
The allergy and hypersensitivity definitions and
semantic framework
The allergy and hypersensitivity definitions
Outside the allergy community, the terms “hypersensitivity”
and “allergy” have often been considered to be synonymous.
However, currently in the field of allergy they receive differ-
ent hierarchical positions since (Fig. 3) “hypersensitivity” is
defined as “conditions clinically resembling allergy that
cause objectively reproducible symptoms or signs, initiated
by exposure to a defined stimulus at a dose tolerated by
normal subjects” and “allergy” as “a hypersensitivity
reaction initiated by proven or strongly suspected immuno-
logic mechanisms” [19]. Therefore, the heading “hypersen-
sitivity” includes allergic hypersensitivity conditions, such as
milk-induced anaphylaxis (IgE-mediated) or antiepileptic-
induced Stevens-Johnson syndrome (non-IgE mediated), as
well as non-allergic hypersensitivity conditions, such as
angiotensin-converting enzyme inhibitor induced angio-
edema or cold-induced urticaria (non-immune mediated
hypersensitivity). An allergic reaction occurs when triggered
by allergens to which the affected individual is sensitized
(i.e., has immune antigen receptors directed against them).
Although the term “intolerance” has been wrongly used to
describe allergic clinical presentations by other specialties
and laypersons, it has been mentioned as a non-allergic
(non-immunological) hypersensitivity condition [50],
out of the area of allergy practice. Therefore, this term
has been added as exclusion of allergy in the new ICD-
11 framework.
Table 1 shows some misunderstandings related to the
concepts of “allergy”, “sensitization”, “atopy” and “atopic
diseases”. The concept of “allergy” is an umbrella that
covers both IgE- and non-IgE mediated conditions with
different degrees of severity and is not synonymous with
“atopy” or in cases of increased isolated total or specific
IgE serum level. The diagnosis of allergy is based on a
compatible clinical history and in vivo and/or in vitro tests
to prove underlying (allergy) mechanism and etiology
(cause). Therefore the tests cannot be used in isolation,
for example to screen the general population for allergic
conditions, because many people are sensitized, but have
no allergic condition. The term atopy is used when indi-
viduals have an IgE sensitization as documented by IgE
antibodies in serum or by a positive skin prick test.
Since the concept of “hypersensitivity” covers many dif-
ferent conditions such as asthma, rhinitis, anaphylaxis,
drug, food, and insect hypersensitivity, eczema, urticaria
and angioedema, we have focused on the current defini-
tions of conditions covered by the allergy specialty (Table 2)
and to update them to the new ICD-11 “Allergic and
hypersensitivity conditions” chapter. As shown in Table 2,
the semantic framework on using the nomenclature “aller-
gic” and “non-allergic” has been extended to most of the
conditions. We would like to highlight the terminology
used for “anaphylaxis” now used throughout the world to
cover both allergic and non-allergic anaphylaxis. The term
“anaphylactoid”, that was used to connote non-allergic ana-
phylaxis, has fallen into disuse. Another example is the
term “intrinsic” or “extrinsic” used for asthma. These terms
are still listed in the ICD-10 (and adaptations) and used to
be in use to evoke underlying mechanism. However, follow-
ing the new concepts, the terms have been tuned to “aller-
gic asthma” and “non-allergic asthma” and now
implemented into the new ICD-11.
The development of medicine and new technological
knowledge has dramatically changed the landscape in
which we practice medicine. Within the specialty of clin-
ical allergy, many diagnostic procedures have emerged to
support the correct diagnosis of allergic and hypersensitiv-
ity conditions [48] (Table 3). However, apart from minor
modifications, the in vivo tests, such as skin prick and
patch tests, still resemble the original methods described.
In this regard, we would like to further underline that skin
tests and in vitro procedures (Table 3) are not usually indi-
cated as a screening of the general population (without
symptoms and a working or suspected diagnosis). The
tests are used to support diagnosis in patients with a sus-
picious history and have to be carefully interpreted. The
management of allergy and hypersensitivity has also been
affected with the implementation of novel therapeutic
agents, drug classes and new devices to optimize the best
treatment of these patients. For this reason, the concepts
used for desensitization/tolerance induction and immuno-
therapy have been recently reviewed. From the allergy spe-
cialty perspective, all allergen immunotherapies (AIT) are
desensitization procedures. However, the desensitization/
tolerance induction procedures can be used with aller-
gens (procedure named AIT) or other products not
Table 3 Main current diagnostic procedures for allergy/
hypersensitivity (adapted from [48])
IgE-mediated hypersensitivity
diagnostic
procedures
T-Lymphocyte-mediated
hypersensitivity diagnostic
procedures
In vitro
− Serum allergen specific-IgE
− Serum (or plasma) tryptase
− Basophil activation test (BAT)
− Cellular Antigen Stimulation Test
(CAST)- Enzyme linked Immuno
Sorbent Assay (ELISA)
In vitro
− Lymphocyte transformation
blood test
− Enzyme-Linked ImmunoSpot
(ELISPOT)
− CD69 expression
In vivo
− Skin tests
• Skin prick tests
• Intradermal skin tests
− Provocation test
In vivo
− Skin tests
• Skin patch tests/Photopatch
tests
• Intradermal skin tests
− Provocation test
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made of allergens (e.g., AIT for allergic rhinitis), pro-
cedure named allergy immunotherapy (e.g., the anti-IgE
monoclonal antibody omalizumab for asthma). It can
address both allergic hypersensitivity conditions, such
as IgE-mediated food-induced anaphylaxis (e.g., milk-
induced anaphylaxis), as well as non-immune-mediated
hypersensitivity conditions (e.g., NSAIDs-exacerbated
respiratory disease) [49].
Conclusion
The allergic and hypersensitivity in process
The allergic and hypersensitivity concepts have been
evolving substantially and efforts have been addressed to
allow harmonization of work definitions and terminology.
The classification systems are used to categorize ideas and
concepts to support the real-life management decision-
making and are, in general, translated automatically into
codes. In clinical practice, clinicians select diagnostic la-
bels based on classification knowledge. This current re-
view intends to be accepted and used universally by all
health professionals involved in diseases’ classification and
coding and, therefore, contribute to improve care and out-
comes in this increasing sub-section of the world’s popula-
tion (Fig. 4).
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